DexCom Reports Q3 Revenue of $1.34 Billion, Raises 2026 Guidance
DexCom reported Q3 2026 adjusted EPS of $0.73 and raised full-year revenue guidance to $5.20 billion–$5.25 billion. Revenue was $1.34 billion, versus FactSet consensus of $1.33 billion; adjusted EPS compared with an analyst estimate of $0.67.
DexCom announced its third-quarter 2026 financial results, reporting revenue of $1.34 billion, which surpassed the FactSet consensus estimate of $1.33 billion. The company also posted an adjusted earnings per share of $0.73, beating the analyst estimate of $0.67. Following these results, DexCom updated its full-year 2026 revenue guidance to a range of $5.20 billion to $5.25 billion. The company's performance reflects continued growth in its continuous glucose monitoring business.